Choose clients as you would friends. - Charlie Munger
ImmunoGen (NASDAQ:IMGN) is a highly promising bioscience that is harnessing the power of ADC to deliver the next-generation cancer treatment. The company has an invaluable asset, ADC that, in and of itself, is licensed to other strong companies. In addition, the firm is leveraging on the far-reaching underlying science of ADC to brew an in-house pipeline of superb molecules (that are highly likely to become blockbusters in the foreseeable future). As reflective of the increasing intrinsic value, the shares have been trading northbound. Accordingly, the stock exchanged hands $6.61 higher at $11.14 (for over 150% profits during the past 52-week). The elephant in the room is where the share price is heading. In this research, we’ll elucidate the fundamentals as well as other catalytic developments that can catapult the shares to a new high.
